New research findings on prostate cancer in Germany

New research findings from a Movember-funded clinical trial called ENZA-p reveals a world-first combination treatment approach that has led to longer and better-quality lives for men living with incurable prostate cancer.

A Peter MacCallum Cancer Centre study, part-funded by Movember, has led to a break-through in the treatment of early-stage prostate cancer.

Research by The Lancet says that annual prostate cancer cases and deaths are projected to rise.

Movember funding has supported ground-breaking new research which harnesses the use of artificial intelligence to improve prostate cancer treatment.

A ground-breaking trial supported by Movember has shown that combining two different drugs could delay the progression of advanced prostate cancer by an average of five months.

Movember funding has supported a world-first trial which has shown Lu-PSMA therapy is safe and effective for men with newly diagnosed localised prostate cancer.